Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

"Findings continue to support the role of anti-CD19 B-cell depletion therapy for the treatment of gMG." Myasthenia gravis is ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

The rationale for targeting BTK is that it allows selective inhibition of the auto-reactive B cells that are behind the pathologies of MS, myasthenia gravis and other autoimmune disorders.

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis.

Nicholas J. Silvestri, MD, expects that the upcoming 2025 American Academy of Neurology Annual Meeting in San Diego will be an exciting event for the field of myasthenia gravis (MG), with ...

lead cell therapy candidate, in participants with generalized myasthenia gravis (MG). MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by ...

As described in the journal Cell, the researchers analyzed the autoantibodies of six different myasthenia gravis patients. They discovered that these antibodies can disrupt the normal receptor ...

According to Estacio, treatment for myasthenia gravis involves careful use of anticholinesterase and immunosuppresant drugs such as corticosteroids. "In some cases, there is plasma exchange or ...

"Findings continue to support the role of anti-CD19 B-cell depletion therapy for the treatment of gMG." Myasthenia gravis is a rare neuromuscular disorder caused by the production of pathogenic ...